European Commission approves the first single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX (interferon beta-1a) administration “At Biogen Idec, our commitment ...

AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec The Avonex Pen (interferon beta-1a 30mcg/0.5mL solution for injection), the first IM autoinjector for chronic use in ...

Dosing Enhancements May Improve Treatment Experience for Patients Receiving AVONEX® (interferon beta-1a) for Multiple Sclerosis WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) ...

-- First single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX recommended for approval in the European Union and authorised in Canada -- AVONEX PEN is designed ...

According to Drugmaker Biogen Idec this Tuesday, it has received U.S. approval for an easier-to-use form of its multiple sclerosis injection Avonex. The Food and Drug Administration approved the ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Biogen Idec Canada Inc today announced AVONEX ® PEN ™ is now available for patients with relapsing multiple sclerosis (MS) and patients with a single ...

For patients suffering from Multiple Sclerosis (MS), a disease of the nervous system, treatment with long painful needles may soon be a thing of the past as shorter and thinner needle injections are ...

Study showed 94% of patients preferred new device over existing Avonex prefilled syringe. The European regulatory authorities approved Biogen Idec’s single-use intramuscular autoinjector, Avonex PEN, ...

Avonex is a prescription drug that treats relapsing forms of multiple sclerosis (MS) in adults, such as relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.